Can a mobile pharmacy help people stick with addiction treatment?

NCT ID NCT07176351

Not yet recruiting Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This pilot study will test whether giving a monthly extended-release buprenorphine injection (BRIXADI) from a mobile pharmacy clinic is acceptable and practical for people with opioid use disorder. About 60 participants will receive the shot for 6 months, and researchers will track how many stay on treatment. The goal is to see if this approach can make addiction care more accessible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: buprenorphine (extended-release injection, BRIXADI)
What this could lead to: If successful, this could show that delivering long-acting addiction medication via a mobile clinic is a practical way to reach people who might not otherwise get treatment.
What could go wrong: This is a small pilot study with only 60 participants, so results may not apply broadly. It focuses on feasibility, not effectiveness, and participants must stay on medication for 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Yale School of Medicine

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.